Literature DB >> 19827950

Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population.

John D Scott1, Anna Wald, Mari Kitahata, Elizabeth Krantz, Linda Drolette, Lawrence Corey, Chia C Wang.   

Abstract

This retrospective cohort study of HIV/hepatitis C virus (HCV) coinfected patients evaluated time trends and rates of HCV evaluation for patients seen between January 1, 1997 and October 30, 2004. Survival analysis and Cox proportional hazards modeling were used to describe the time to evaluation and covariates associated with this outcome. Patients were predominantly white and male. Of 248 eligible patients, 108 (44%) were evaluated for HCV treatment. The median time to evaluation was 2.98 years. Of 108 evaluated, 17 (16%) received at least one dose of interferon and/or ribavirin. The median time to treatment after being evaluated was 1.39 years. Of the 17 (35%) treated 6 patients had a sustained virologic response, but only 2.4% of the original number of patients were cured. Approximately one half of patients in an HIV-specialty clinic were evaluated for HCV therapy and 16% received treatment, but the median time to treatment from the time of HCV diagnosis was over 4 years. Further efforts to identify and to overcome barriers to HCV treatment are warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19827950      PMCID: PMC2859767          DOI: 10.1089/apc.2009.0099

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  14 in total

1.  Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

Authors:  Fabrice Carrat; Firouzé Bani-Sadr; Stanislas Pol; Eric Rosenthal; Françoise Lunel-Fabiani; Asmae Benzekri; Patrice Morand; Cécile Goujard; Gilles Pialoux; Lionel Piroth; Dominique Salmon-Céron; Claude Degott; Patrice Cacoub; Christian Perronne
Journal:  JAMA       Date:  2004-12-15       Impact factor: 56.272

2.  Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection.

Authors:  Shawn L Fultz; Amy C Justice; Adeel A Butt; Linda Rabeneck; Sharon Weissman; Maria Rodriguez-Barradas
Journal:  Clin Infect Dis       Date:  2003-04-01       Impact factor: 9.079

3.  Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.

Authors:  Y Benhamou; M Bochet; V Di Martino; F Charlotte; F Azria; A Coutellier; M Vidaud; F Bricaire; P Opolon; C Katlama; T Poynard
Journal:  Hepatology       Date:  1999-10       Impact factor: 17.425

4.  Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival.

Authors:  C T Staples; D Rimland; D Dudas
Journal:  Clin Infect Dis       Date:  1999-07       Impact factor: 9.079

5.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

6.  Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy.

Authors:  Ellen M Tedaldi; Rose K Baker; Anne C Moorman; Carlos F Alzola; Jack Furhrer; Robert E McCabe; Kathleen C Wood; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2003-01-14       Impact factor: 9.079

7.  The therapeutic implications of timely linkage and early retention in HIV care.

Authors:  Kimberly B Ulett; James H Willig; Hui-Yi Lin; Justin S Routman; Sarah Abroms; Jeroan Allison; Ashlee Chatham; James L Raper; Michael S Saag; Michael J Mugavero
Journal:  AIDS Patient Care STDS       Date:  2009-01       Impact factor: 5.078

8.  Hepatitis C virus infection in San Francisco's HIV-infected urban poor.

Authors:  Christopher S Hall; Edwin D Charlebois; Judith A Hahn; Andrew R Moss; David R Bangsberg
Journal:  J Gen Intern Med       Date:  2004-04       Impact factor: 5.128

9.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

10.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Authors:  Francesca J Torriani; Maribel Rodriguez-Torres; Jürgen K Rockstroh; Eduardo Lissen; Juan Gonzalez-García; Adriano Lazzarin; Giampiero Carosi; Joseph Sasadeusz; Christine Katlama; Julio Montaner; Hoel Sette; Sharon Passe; Jean De Pamphilis; Frank Duff; Uschi Marion Schrenk; Douglas T Dieterich
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

View more
  16 in total

1.  Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis.

Authors:  Gerald Friedland
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

2.  Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment.

Authors:  Karen Chan Osilla; Glenn Wagner; Jeffrey Garnett; Bonnie Ghosh-Dastidar; Mallory Witt; Laveeza Bhatti; Matthew Bidwell Goetz
Journal:  AIDS Patient Care STDS       Date:  2011-08-08       Impact factor: 5.078

3.  An interrupted time series evaluation of a hepatitis C intervention for persons with HIV.

Authors:  Rae Jean Proeschold-Bell; Bettina Hoeppner; Baishakhi Taylor; Sarah Cohen; Rachel Blouin; Beth Stringfield; Andrew J Muir
Journal:  AIDS Behav       Date:  2011-11

Review 4.  Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.

Authors:  Frederick L Altice; Adeeba Kamarulzaman; Vincent V Soriano; Mauro Schechter; Gerald H Friedland
Journal:  Lancet       Date:  2010-07-31       Impact factor: 79.321

5.  Impact of hepatitis coinfection on healthcare utilization among persons living with HIV.

Authors:  Trevor A Crowell; Stephen A Berry; John A Fleishman; Richard W LaRue; Philip T Korthuis; Ank E Nijhawan; Richard D Moore; Kelly A Gebo
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-01       Impact factor: 3.731

6.  Hepatitis B and C infection and liver disease trends among human immunodeficiency virus-infected individuals.

Authors:  Susan E Buskin; Elizabeth A Barash; John D Scott; David M Aboulafia; Robert W Wood
Journal:  World J Gastroenterol       Date:  2011-04-14       Impact factor: 5.742

Review 7.  Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review.

Authors:  Christine U Oramasionwu; Heather N Moore; Joshua C Toliver
Journal:  AIDS Patient Care STDS       Date:  2014-04-16       Impact factor: 5.078

8.  U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.

Authors:  Keri N Althoff; Kate Buchacz; H Irene Hall; Jinbing Zhang; David B Hanna; Peter Rebeiro; Stephen J Gange; Richard D Moore; Mari M Kitahata; Kelly A Gebo; Jeffrey Martin; Amy C Justice; Michael A Horberg; Robert S Hogg; Timothy R Sterling; Angela Cescon; Marina B Klein; Jennifer E Thorne; Heidi M Crane; Michael J Mugavero; Sonia Napravnik; Gregory D Kirk; Lisa P Jacobson; John T Brooks
Journal:  Ann Intern Med       Date:  2012-09-04       Impact factor: 25.391

Review 9.  Substance abuse treatment in persons with HIV/AIDS: challenges in managing triple diagnosis.

Authors:  Ramani Durvasula; Theodore R Miller
Journal:  Behav Med       Date:  2014       Impact factor: 3.104

Review 10.  Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors.

Authors:  Magdalena Harris; Tim Rhodes
Journal:  Harm Reduct J       Date:  2013-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.